Literature DB >> 1517304

Rapid and efficient purification of cimetropium bromide and mifentidine drug metabolite mixtures derived from microsomal incubates for analysis by mass spectrometry.

M Kajbaf1, M Jahanshahi, K Pattichis, J W Gorrod, S Naylor.   

Abstract

A comparative study of the use of organic solvent extraction versus Sep-Pak C18 cartridges in the recovery and analysis of phase I (unconjugated) drug metabolites using mass spectrometry is presented. Standard mixtures of putative metabolites of the anticholinergic drug cimetropium bromide and the H2-antagonist mifentidine were purified from inactivated liver microsomal preparations using both methods, and subsequently the recovery of each compound was quantitated. In general, the percentage recovery and degree of purification were greater when using Sep-Pak C18 cartridges compared with organic solvent extraction. Even more efficient recovery was achieved when zinc sulphate precipitation of proteins in the liver microsomal mixtures was carried out prior to analysis. Also, the HPLC-grade solvents used in this study contained a variety of ultraviolet-inactive, hydrophobic components. This leads to problems of suppression in fast atom bombardment mass spectrometric analysis. Using Sep-Pak C18 cartridges directly prior to analysis by fast atom bombardment with single or tandem mass spectrometry leads to far superior mass spectral results compared with organic solvent extraction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517304     DOI: 10.1016/0378-4347(92)80506-l

Source DB:  PubMed          Journal:  J Chromatogr


  2 in total

1.  In vitro studies on the metabolic fate of mifentidine, a novel histamine H2-receptor antagonist.

Authors:  K Pattichis; M Kajbaf; J W Gorrod
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Apr-Jun       Impact factor: 2.441

2.  Characterization of N-benzylcarbazole and its metabolites from microsomal mixtures by tandem mass spectrometry.

Authors:  M Ulgen; M Kajbaf; J H Lamb; M Jahanshahi; J W Gorrod; S Naylor
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Oct-Dec       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.